What antigens & molecular markers are targeted for subtyping Non-Hodgkin lymphomas? Key Targets for IVD Assays

For accurate subtyping of Non-Hodgkin lymphomas in diagnostic assays, the essential targets are lineage-defining cell surface antigens (CD19, CD20, CD10 for B cells; CD3, CD4, CD8 for T cells) combined with clonality markers (immunoglobulin gene rearrangements for B-cell lymphomas and T-cell receptor gene rearrangements for T-cell lymphomas). These targets enable both identification of the malignant population and confirmation of its clonal nature—a necessary step for differentiating reactive processes from true lymphoma.

Core Takeaway: Subtyping Non-Hodgkin lymphomas in an IVD assay requires two layers of information: surface antigen profiling to assign lineage (B-cell vs. T/NK-cell) and molecular detection of clonal antigen receptor gene rearrangements to prove malignancy. The primary reference targets are CD19, CD20, and CD10 for B cells, combined with immunoglobulin gene analysis, while T-cell lymphomas demand T-cell receptor gene rearrangements alongside CD3, CD4, and CD8. This dual approach is the foundation of flow cytometry and IHC panels.

Understanding the Diagnostic Needs for Lymphoma Subtyping

Why Surface Antigens Alone Are Insufficient

A reactive lymph node can show an increased number of B or T cells. What distinguishes a lymphoma is the presence of a monoclonal population: all cells derived from a single transformed lymphocyte.

Therefore, an assay must not only identify the cell lineage but also demonstrate that the cells are clonal. This drives the requirement for both phenotypic markers and molecular clonality assays.

The Role of Lineage-Specific CD Antigens

The primary reference and supplementary data converge on a core set of Clusters of Differentiation (CD) that are the backbone of any diagnostic panel. These surface antigens are targeted by high-specificity monoclonal antibodies in flow cytometry and immunohistochemistry.

For B-cell lymphomas (~85% of NHLs):

• CD19 – a pan-B-cell marker present from early development; key for gating B cells.
• CD20 – a B-cell-specific surface protein expressed from pre-B to mature stages; heavily targeted therapeutically and diagnostically.
• CD10 – a marker of germinal center-derived B cells; critical for subtyping follicular lymphoma and diffuse large B-cell lymphoma (DLBCL) subtypes.
• Surface immunoglobulins – light chain restriction (kappa or lambda) is a direct indicator of clonality in B-cell neoplasms.

For T-cell lymphomas (~15% of NHLs):

• CD3 – present on all mature T cells; anchors the T-cell receptor complex.
• CD4 – identifies helper/regulatory T cells.
• CD8 – identifies cytotoxic T cells.
• CD5, CD7 (not in the provided references, but I won’t add) — actually, stick to references. The supplementary mentions CD4 and CD8 for T cell subtypes, so we'll use those. The primary reference only says "T-cell surface markers" so I'll incorporate CD3, CD4, CD8 as per supplementary. I can also note CD4 and CD8 help subtype mature T-cell lymphomas.

For NK-cell lymphomas (a subset of T/NK-cell NHLs):

• CD16 and CD56, from the supplementary reference, are essential for identifying NK-cell lineage. Incorporating these into a panel allows detection of rare NK-cell lymphomas.

The Non-Negotiable Molecular Markers

The primary reference explicitly states that immunoglobulin gene rearrangements are targeted for B-cell lymphomas, while T-cell receptor (TCR) gene rearrangements are targeted for T-cell lymphomas.

These molecular tests are performed using PCR-based methods to detect clonal V(D)J rearrangements. A single dominant amplicon confirms clonality, distinguishing a malignant population from a polyclonal reactive expansion.

Building a Complete IVD Assay Panel

Integrating Surface and Molecular Targets

A robust diagnostic assay flows like this:

1. Lineage gating with broad markers: CD19 or CD20 for B cells; CD3 for T cells. CD16/CD56 if NK-cell lineage is suspected.
2. Subset characterization with CD10 on B cells (germinal center vs. non-germinal center), and CD4/CD8 on T cells.
3. Clonality confirmation using either surface immunoglobulin light chain restriction (by flow cytometry) or TCR/Ig gene rearrangement analysis (by PCR).

This combined approach provides high sensitivity and specificity for lymphoma subtyping.

Marker Selection for Accurate Phenotyping

When developing raw materials for diagnostic antibodies, focusing on these CD antigens ensures precise cell counting and lineage tracing. The supplementary reference emphasizes that high-affinity antibodies against CD19, CD21, CD3, CD4, CD8, CD16, and CD56 are the foundation for immune disorder monitoring. For lymphoma subtyping, CD19 is prioritized over CD21, but CD21 can be useful in certain mature B-cell neoplasms (e.g., follicular dendritic cell meshworks in follicular lymphoma). However, our primary reference focuses on CD19, CD20, CD10, so I'll keep the emphasis there.

Understanding the Trade-offs

Limitations of Antigen-Based Assays

• Antigen loss or downregulation: Some aggressive lymphomas weakly express or lose lineage markers like CD20, leading to false-negative phenotyping. Diagnosis must rest on molecular clonality results.
• Overlap with reactive conditions: CD10 can be positive in germinal center hyperplasia. Without light chain restriction or molecular clonality, a reactive condition may be misclassified.
• NK-cell ambiguity: NK cells share markers (CD16, CD56) with a subset of T cells. Accurate subtyping requires simultaneous assessment of CD3 (surface vs. cytoplasmic) and TCR gene rearrangement status to separate true NK-cell from T-cell lymphomas.

Pitfalls of Molecular Clonality Testing

• Pseudoclonality: In specimens with very few lymphocytes, PCR may amplify a falsely dominant clone. Repeat testing or alternative clonality targets mitigate this.
• Lineage infidelity: Rare B-cell lymphomas co-express T-cell markers, potentially misleading a panel that relies solely on lineage-specific gating. Comprehensive antigen profiles (e.g., CD19 + CD10 + CD20, not a single marker) are essential.

Making the Right Choice for Your Assay Development

Your target approach depends on the assay’s clinical goal and platform (flow cytometry vs. IHC vs. PCR).

• If your primary focus is rapid, first-line lymphoma screening: Incorporate CD19, CD20, and CD10 with surface immunoglobulin light chain analysis to catch the majority of B-cell neoplasms at the phenotyping stage.
• If your primary focus is accurate T-cell lymphoma subtyping: Combine CD3, CD4, and CD8 with a PCR-based TCR gene rearrangement assay. Do not omit the molecular clonality test—it is the definitive gold standard.
• If your primary focus is detecting rare entities like NK-cell lymphomas: Add CD16 and CD56 to your flow cytometry panel, and always correlate with cytoplasmic CD3 and negative TCR rearrangement.
• If your primary focus is manufacturing high-affinity diagnostic antibodies: Prioritize raw material development against CD19, CD20, CD10, CD3, CD4, CD8, CD16, and CD56, as these antigens underpin nearly every NHL subtyping panel.

The power of your assay lies in the precise combination of a lineage-identifying surface antigen and a clonality-proving molecular marker—never one without the other.

Summary Table:

Accelerate Your Lymphoma Diagnostic Assay Development

Developing high-specificity diagnostic panels for Non-Hodgkin lymphoma subtyping demands premium raw materials and rigorous validation. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.

Whether you need high-affinity monoclonal antibodies against target CD antigens (CD19, CD20, CD10, CD3, CD4, CD8, CD16, CD56) or customized technical support for assay optimization, we ensure batch-to-batch consistency and supply reliability.

Ready to bring your diagnostic assay from concept to market? Contact CamelBio today to speak with our technical experts!